Biotech Values

[mcbio]

BGNE -

BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer.

BeiGene claims their PD-1 may be differentiated from others given its ability to bind the Fc gamma receptor I has been specifically engineered out and that it has unique binding characteristics to PD-1 that may offer superior target specificity. Anyone have any comments on these specific claims, particularly the former? How valid are such claims likely to be?